6|9|08 Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions 4|2|08 Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis 1|30|08 Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes 9|17|07 Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis / MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius 6|8|07 Radius Presents Positive Results from Phase IB Clinical Trial of BA058 and Preclinical Study of RAD1901 at ENDO 2007 4|2|07 Radius Raises $57.5 Million in Second Private Financing Round 3|20|07 Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis 1|2|07 Radius Appoints Nick Harvey Senior Vice President and CFO 8|7|06 Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists 6|29|06 Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs 4|12|06 Radius Appoints Louis O’Dea Senior Vice President and Chief Medical Officer 12|13|05 Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 / PTHrP Analog in Phase I Clinical Trials 11|12|04 Nuvios* Names Dr. Christopher Glass to Scientific Advisory Board 10|4|04 Nuvios* Names C. Richard Lyttle President and CEO *Name changed to Radius effective December 2005
Radius Selects First Preclinical Candidate from SARM Discovery Program for the Treatment of Muscle Loss and Other Musculoskeletal Conditions
4|2|08
Radius Completes Enrollment of Phase II Clinical Trial of BA058 for Osteoporosis
1|30|08
Radius Announces Launch of RAD1901 Clinical Program for the Treatment of Hot Flashes
9|17|07
Radius Grants Major Pharmaceutical Company Exclusive Option to License BA058 for Osteoporosis / MPM Bio IV NVS Strategic Fund L.P. invests $10 million in Radius
6|8|07
Radius Presents Positive Results from Phase IB Clinical Trial of BA058 and Preclinical Study of RAD1901 at ENDO 2007
4|2|07
Radius Raises $57.5 Million in Second Private Financing Round
3|20|07
Radius Begins Phase II Clinical Trial of BA058 for Osteoporosis
1|2|07
Radius Appoints Nick Harvey Senior Vice President and CFO
8|7|06
Radius Licenses Worldwide Exclusive Rights to Estrogen Receptor-Beta Agonists
6|29|06
Radius Announces Licensing Agreement to Develop and Commercialize Eisai SERMs
4|12|06
Radius Appoints Louis O’Dea Senior Vice President and Chief Medical Officer
12|13|05
Radius Announces Licensing Agreement for Ipsen Osteoporosis Proprietary Molecule BA058 / PTHrP Analog in Phase I Clinical Trials
11|12|04
Nuvios* Names Dr. Christopher Glass to Scientific Advisory Board
10|4|04
Nuvios* Names C. Richard Lyttle President and CEO
*Name changed to Radius effective December 2005
© 2005 Radius Health, Inc. | Privacy Policy | Home | Contact
300 Technology Square, Fifth Floor, Cambridge, MA 02139 Tel: (617) 551-4700 | Fax: (617) 551-4701
